Kalevi Kairemo

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

33h-index4.0kcitations310works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Radiopharmaceutical Chemistry and Applications(116), Prostate Cancer Treatment and Research(72), Medical Imaging Techniques and Applications(58), Virus-based gene therapy research(58), Cancer Research and Treatments(53)

Publications310 total

Prognostic Implication of [18F]FDG PET and Its Metabolic Changes in Patients with Advanced Metastatic Neuroendocrine Tumors Undergoing Rechallenge PRRT: Final Results from a Multicenter 10-Year Survival
World Journal of Nuclear Medicine·2025Open Access
Prognostic implications of [¹⁸F]FDG PET and metabolic changes in patients with advanced metastatic neuroendocrine tumors undergoing rechallenge PRRT: final results from a multicenter 10-year survival WARMTH study
Theranostics·2025· 1 citedOpen Access
Hepatic and Pulmonary Vasoactive Response Triggered by Potentially Hazardous Chemicals After Passing Through the Gut Mucosa
Diagnostics·2025Open Access
First-in-human study of DGPR1008 for intraoperative fluorescence imaging of prostate-specific membrane antigen-positive prostate cancer in patients undergoing radical prostatectomy
Translational Andrology and Urology·2025Open Access
International guidelines on the diagnosis and treatment of NUT carcinoma
The Innovation·2025Open Access
Hepatic and Pulmonary Vasoactive Response Triggered by Potentially Hazardous Chemicals After Passing Through the Gut Mucosa<sub></sub>
Preprints.org·2025Open Access
Overview of Adverse Reactions of Radiopharmaceuticals
Clinical Oncology·2025Open Access
Management Based on Pretreatment PSMA PET of Patients with Localized High-Risk Prostate Cancer Part 2: Prediction of Recurrence—A Systematic Review and Meta-Analysis
Cancers·2025· 2 citedOpen Access
Lu-177-PSMA Treatment in Prostate Cancer
2025
18F-FDHT-PET Imaging in the Management of Hormone-Dependent Prostate Cancer
2025
Multicenter Trials of Prostate Radioligand Therapy (PRLT) in Castration-Resistant Cancer
2025
Radium-223 Dichloride (Ra-223) for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2025
PSMA-PET in Prostate Cancer
2025
Briefly About Radiation Therapy
2025
18F-FLT PET/CT in Prostate Adenocarcinoma
2025
Brief Overview of Prostate Cancer Treatment Modalities
2025
Public Appearance Because of Nuclear Oncology (Pictorial Essay)
2025
Immunoscintigraphy and Radioimmunotherapy of Prostate Cancer Including Own Personal Journey: Anti-PAP and Anti-PSMA Antibodies
2025
PET/CT for Radiation Therapy Planning of Prostate Cancer
2025
18F-Fluciclovine (18F-FACBC) Positron Emission Tomography in Prostate Cancer
2025
page 1 of 16Next →

Frequent Co-authors

Akseli Hemminki(10), Kaarina Partanen(9), Timo Joensuu(8), Finn Edler von Eyben(6), Timo Joensuu(6), Sari Pesonen(5), Tuomo Alanko(5), Irene Virgolini(5), Anna Kanerva(5), Minna Oksanen(5), Antti Jekunen(5), Oula Peñate Medina(4), Tuuli Ranki(4), Johan Lundin(4), Nina Linder(4), Riku Turkki(4), Ari Ristimäki(4), Matti Kankainen(4), Elina Haavisto(4), Juuso Juhila(4)